With which condition should the nurse expect that a decrease in serum osmolality will occur?

Practice Essentials

Hyponatremia—defined as a serum sodium concentration of less than 135 mEq/L—is the most commonly encountered and important electrolyte imbalance that can be seen in isolation or, as is most often the case, as a complication of other medical illnesses (eg, heart failure, liver failure, kidney failure, pneumonia, cancer). [1, 2] The normal serum sodium concentration is 135-145 mEq/L. Hyponatremia is classified in adults according to serum sodium concentration, as follows [3] :

  • Mild: 130-134 mmol/L

  • Moderate: 125-129 mmol/L

  • Profound or severe: < 125 mmol/L

Correction of hyponatremia varies according to its source, its severity, and its duration. In patients whose hyponatremia has a known duration of > 48 hours, treatment must be calibrated to avoid osmotic demyelination syndrome (ODS), which may result from overly rapid correction.

Signs and symptoms

Symptoms range from nausea and malaise, in those with mild reduction in the serum sodium, to lethargy, decreased level of consciousness, headache, and (with severe hyponatremia) seizures and coma. Overt neurologic symptoms most often are due to very low serum sodium levels (usually < 115 mEq/L), resulting in intracerebral osmotic fluid shifts and brain edema.

Hyponatremia can be classified according to effective osmolality, as follows:

  • Hypertonic hyponatremia

  • Isotonic hyponatremia

  • Hypotonic hyponatremia – typically considered true hyponatremia

Hypotonic hyponatremia can be further subclassified according to volume status, as follows:

  • Hypervolemic hyponatremia: Increase in total body sodium with greater increase in total body water

  • Euvolemic hyponatremia: Normal body sodium with increase in total body water

  • Hypovolemic hyponatremia: Decrease in total body water with greater decrease in total body sodium

See Presentation for more detail.

Diagnosis

Three laboratory tests—serum osmolality, urine osmolality, and urinary sodium concentration—are essential in the evaluation of patients with hyponatremia. Together with the history and the physical examination, those tests help to establish the primary underlying etiologic mechanism in an algorithmic fashion.

Serum osmolality

Serum osmolality readily differentiates between true hyponatremia (hypotonic hyponatremia) and pseudohyponatremia. The latter may be secondary to hyperlipidemia or hyperproteinemia (isotonic hyponatremia), or may be hypertonic hyponatremia associated with elevated glucose, mannitol, glycine (posturologic or postgynecologic procedure), sucrose, or maltose (contained in IgG formulations).

Urine osmolality

Urine osmolality helps differentiate between conditions associated with the presence or absence of antidiuretic hormone (ADH), also called arginine vasopressin. A dilute urine (urinary osmolality < 100 mOsm/kg) and hypotonic hyponatremia generally results from conditions that overwhelm the kidney’s capacity to excrete free water (as in primary polydipsia) or conditions that truncate the amount of free water that can be excreted, typically due to low solute load (as in tea and toast diet). A urine osmolality greater than 100 mOsm/kg indicates impaired ability of the kidneys to dilute the urine, usually due to physiologic or non-physiologic secretion of ADH. Some uncommon conditions may have either low or high urinary osmolality, depending on the treatment initiated.

Urinary sodium concentration

Urinary sodium concentration helps to differentiate between hyponatremia secondary to hypovolemia and syndrome of inappropriate antidiuretic hormone secretion (SIADH). In SIADH and salt-wasting syndrome the urine sodium is greater than 20-40 mEq/L. In hypovolemia, the urine sodium typically measures less than 20 mEq/L. However, if sodium intake in a patient with SIADH or salt-wasting happens to be low, then urine sodium may fall below 20 mEq/L.

See Workup for more detail.

Management

Hypotonic hyponatremia accounts for most clinical cases of hyponatremia and can be treated with fluid restriction. The treatment of hypertonic hyponatremia and pseudo-hyponatremia is directed at the underlying disorder, in the absence of symptoms.

Acute hyponatremia (duration < 48 hours) can be safely corrected more quickly than chronic hyponatremia. The rate of correction for chronic hyponatremia (duration of > 48 hours or unknown) should be tailored according to the severity of the hyponatremia so as to avoid overcorrection and risk of ODS, but should be limited to 4-8 mEq/L per 24 hours.

Intravenous fluids and water restriction

Patients with overt symptoms (eg, seizures, severe neurologic deficits) and generally those with severe hyponatremia should be treated with hypertonic (3%) saline bolus to increase serum sodium concentration and mitigate their symptoms. In patients with moderate symptoms, a slow infusion of hypertonic saline can be considered. Patients who are asymptomatic or have mild symptoms, will rarely require hypertonic saline.

Administer isotonic saline to patients who are hypovolemic to replace the contracted intravascular volume. Patients with hypovolemia secondary to diuretics may also need potassium repletion. Note that potassium, like sodium, is osmotically active.

Treat patients who are hypervolemic with fluid restriction, with or without loop diuretics, and correction of the underlying condition. The use of a vasopressin V2 receptor antagonist may be considered as second-line therapy.

For euvolemic, asymptomatic hyponatremic patients, free-water restriction is generally the treatment of choice. There is no role for hypertonic saline in these patients.

Pharmacologic treatment

Two vasopressin receptor antagonists, conivaptan (Vaprisol) and tolvaptan (Samsca), are approved for treatment of euvolemic and hypervolemic hyponatremia.

Conivaptan, a V1A and V2 vasopressin receptor antagonist, is available only for intravenous use and is approved for use in the hospital setting for euvolemic and hypervolemic hyponatremia. It is contraindicated in hypovolemic patients.

Tolvaptan, a selective oral vasopressin V2-receptor antagonist is indicated for hypervolemic and euvolemic hyponatremia. It can be used for hyponatremia associated with congestive heart failure and SIADH and must be initiated or reinitiated in hospital environment.

Additional options include the following:

  • Oral urea is an osmotic agent that can increase obligatory free-water excretion.

  • Sodium chloride tablets, when used with loop diuretics, can enhance water excretion.

  • Loop diuretics can be used in hypervolemic hyponatremia to increase free water excretion.

See Treatment and Medication for more detail.

With which condition should the nurse expect that a decrease in serum osmolality will occur?

Pathophysiology

Hypo-osmolality (serum osmolality < 275 mOsm/kg) always indicates excess total body water relative to body solutes or excess water relative to solute in the extracellular fluid (ECF), as water moves freely between the intracellular and the extracellular compartments. This imbalance can be due to solute depletion, solute dilution, or a combination of both.

Under normal conditions, renal handling of water is sufficient to excrete as much as 15-20 L of free water per day. Further, the body's response to a decreased osmolality is decreased thirst. Thus, hyponatremia can occur only when some condition impairs normal free-water excretion. [4]

Generally, hyponatremia is of clinical significance when it reflects a drop in the serum osmolality (ie, hypotonic hyponatremia), which is measured directly via osmometry or is calculated as 2(Na) mEq/L + serum glucose (mg/dL)/18 + BUN (mg/dL)/2.8. Note that urea is not an ineffective osmole, so when the urea levels are very high (as seen in azotemia, the measured osmolality should be corrected for the contribution of urea (measured serum osmolality – BUN (mg/dL)/2.8).

The recommendations for treatment of hyponatremia rely on the current understanding of central nervous system (CNS) adaptation to an altered serum osmolality. [5]  In the setting of an acute drop in the serum osmolality, neuronal cell swelling occurs due to the water shift from the extracellular space to the intracellular space (ie, Starling forces). Swelling of the brain cells elicits the following two osmoregulatory responses:

  • It inhibits both arginine vasopressin secretion from neurons in the hypothalamus and hypothalamic thirst center. This leads to excess water elimination as dilute urine.

  • There is an immediate cellular adaptation with loss of electrolytes, and over the next few days, a more gradual loss of organic intracellular osmolytes. [6]

Therefore, correction of hyponatremia must take into account the chronicity of the condition. Acute hyponatremia (duration < 48 h) can be corrected more quickly than chronic hyponatremia. Most individuals who present with symptomatic hyponatremia, versus individuals who develop hyponatremia in an inpatient setting, have had hyponatremia for some time, so their condition is chronic, and correction should proceed accordingly. Overly rapid correction of serum sodium levels in these individuals can precipitate a severe neurologic complication, ODS. Consequently, when the duration of hyponatremia is uncertain, the condition should be considered chronic.

Epidemiology

United States

The incidence of hyponatremia depends largely on the patient population and the criteria used to establish the diagnosis. Among hospitalized patients, 15-20% have a serum sodium level of < 135 mEq/L, while only 1-4% have a serum sodium level of less than 130 mEq/L. The prevalence of hyponatremia is lower in the ambulatory setting.

The US armed forces reported 1579 incident diagnoses of exertional hyponatremia among active service members from 2003 through 2018, for a crude overall incidence rate of 7.2 cases per 100,000 person-years. Cases occurred both in training facilities and theaters of war. Diagnosis and treatment without hospitalization was accomplished in 86.3% of cases. [7]

Mortality/morbidity

Severe hyponatremia (< 125 mEq/L) has a high mortality rate. In patients whose serum sodium level falls below 105 mEq/L, and especially in alcoholics, the mortality is over 50%. [8]

In patients with acute ST-elevation myocardial infarction (MI), the presence of hyponatremia on admission or early development of hyponatremia is an independent predictor of 30-day mortality, and the prognosis worsens with the severity of hyponatremia. [9] In hospitalized survivors of acute MI, the presence of hyponatremia at discharge is an independent predictor of 12-month mortality. [10]

Similarly, cirrhotic patients with persistent ascites and a low serum sodium level who are awaiting transplant have a high mortality risk despite low- severity Model for End-Stage Liver Disease (MELD) scores (see the MELD Score calculator). The independent predictors—ascites and hyponatremia—are findings indicative of hemodynamic decompensation. [11, 12, 13]

In patients with chronic kidney disease, hyponatremia and hypernatremia are associated with an increased risk for all-cause mortality and for deaths unrelated to cardiovascular problems or malignancy. Hyponatremia is also linked to an increased risk for cardiovascular- and malignancy-related mortality in these patients. [14]

Hyponatremia affects all races.

No sexual predilection exists for hyponatremia. However, symptoms are more likely to occur in young women than in men. Hyponatremia is more common in elderly persons partially because of higher rate of comorbid conditions (eg, heart, liver, or kidney failure) that can lead to hyponatremia.

  1. Hoorn EJ, Zietse R. Diagnosis and Treatment of Hyponatremia: Compilation of the Guidelines. J Am Soc Nephrol. 2017 May. 28 (5):1340-1349. [QxMD MEDLINE Link]. [Full Text].

  2. Castillo JJ, Glezerman IG, Boklage SH, Chiodo J 3rd, Tidwell BA, Lamerato LE, et al. The occurrence of hyponatremia and its importance as a prognostic factor in a cross-section of cancer patients. BMC Cancer. 2016 Jul 29. 16:564. [QxMD MEDLINE Link]. [Full Text].

  3. [Guideline] Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier RW, Sterns RH, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013 Oct. 126 (10 Suppl 1):S1-42. [QxMD MEDLINE Link].

  4. Singhi S, Jayashre M. Free water excess is not the main cause for hyponatremia in critically ill children receiving conventional maintenance fluids. Indian Pediatr. 2009 Jul. 46(7):577-83. [QxMD MEDLINE Link].

  5. Silver SM, Schroeder BM, Bernstein P, Sterns RH. Brain adaptation to acute hyponatremia in young rats. Am J Physiol. 1999 Jun. 276 (6 Pt 2):R1595-9. [QxMD MEDLINE Link].

  6. Gross P, Reimann D, Henschkowski J, Damian M. Treatment of severe hyponatremia: conventional and novel aspects. J Am Soc Nephrol. 2001 Feb. 12 Suppl 17:S10-4. [QxMD MEDLINE Link]. [Full Text].

  7. Update: Exertional hyponatremia, active component, U.S. Armed Forces, 2003-2018. MSMR. 2019 Apr. 26 (4):27-31. [QxMD MEDLINE Link].

  8. Chawla A, Sterns RH, Nigwekar SU, Cappuccio JD. Mortality and serum sodium: do patients die from or with hyponatremia?. Clin J Am Soc Nephrol. 2011 May. 6 (5):960-5. [QxMD MEDLINE Link].

  9. Goldberg A, Hammerman H, Petcherski S, Zdorovyak A, Yalonetsky S, Kapeliovich M, et al. Prognostic importance of hyponatremia in acute ST-elevation myocardial infarction. Am J Med. 2004 Aug 15. 117 (4):242-8. [QxMD MEDLINE Link].

  10. Bae MH, Kim JH, Jang SY, Park SH, Lee JH, Yang DH, et al. Hyponatremia at discharge as a predictor of 12-month clinical outcomes in hospital survivors after acute myocardial infarction. Heart Vessels. 2017 Feb. 32 (2):126-133. [QxMD MEDLINE Link].

  11. Heuman DM, Abou-Assi SG, Habib A, Williams LM, Stravitz RT, Sanyal AJ, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology. 2004 Oct. 40 (4):802-10. [QxMD MEDLINE Link].

  12. Kim MY, Baik SK, Yea CJ, Lee IY, Kim HJ, Park KW, et al. Hepatic venous pressure gradient can predict the development of hepatocellular carcinoma and hyponatremia in decompensated alcoholic cirrhosis. Eur J Gastroenterol Hepatol. 2009 Nov. 21 (11):1241-6. [QxMD MEDLINE Link].

  13. Ginés P, Berl T, Bernardi M, Bichet DG, Hamon G, Jiménez W, et al. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology. 1998 Sep. 28 (3):851-64. [QxMD MEDLINE Link].

  14. Huang H, Jolly SE, Airy M, Arrigain S, Schold JD, Nally JV, et al. Associations of dysnatremias with mortality in chronic kidney disease. Nephrol Dial Transplant. 2017 Jul 1. 32 (7):1204-1210. [QxMD MEDLINE Link]. [Full Text].

  15. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999 Aug 19. 341 (8):577-85. [QxMD MEDLINE Link]. [Full Text].

  16. Bettari L, Fiuzat M, Shaw LK, Wojdyla DM, Metra M, Felker GM, et al. Hyponatremia and long-term outcomes in chronic heart failure--an observational study from the Duke Databank for Cardiovascular Diseases. J Card Fail. 2012 Jan. 18 (1):74-81. [QxMD MEDLINE Link].

  17. Hew-Butler T, Loi V, Pani A, Rosner MH. Exercise-Associated Hyponatremia: 2017 Update. Front Med (Lausanne). 2017. 4:21. [QxMD MEDLINE Link].

  18. Lien YH. Antidepressants and Hyponatremia. Am J Med. 2018 Jan. 131 (1):7-8. [QxMD MEDLINE Link].

  19. Lu X, Wang X. Hyponatremia induced by antiepileptic drugs in patients with epilepsy. Expert Opin Drug Saf. 2017 Jan. 16 (1):77-87. [QxMD MEDLINE Link].

  20. Hillier TA, Abbott RD, Barrett EJ. Hyponatremia: evaluating the correction factor for hyperglycemia. Am J Med. 1999 Apr. 106 (4):399-403. [QxMD MEDLINE Link].

  21. Coakley JC, Vervaart PP, McKay MR. Factitious hyponatremia in a patient with cholestatic jaundice following bone marrow transplantation. Pathology. 1986 Jan. 18 (1):158-9. [QxMD MEDLINE Link].

  22. Issa MM, Young MR, Bullock AR, Bouet R, Petros JA. Dilutional hyponatremia of TURP syndrome: a historical event in the 21st century. Urology. 2004 Aug. 64 (2):298-301. [QxMD MEDLINE Link].

  23. Yang CH, Lin YC, Chou PH, Chen HC, Chan CH. A Case Report of Late Onset Mania Caused by Hyponatremia in a Patient With Empty Sella Syndrome. Medicine (Baltimore). 2016 Feb. 95 (6):e2629. [QxMD MEDLINE Link].

  24. Sterns RH. The syndrome of inappropriate antidiuretic hormone secretion of unknown origin. Am J Kidney Dis. 1999 Jan. 33 (1):161-3; discussion 163-5. [QxMD MEDLINE Link].

  25. Pham PC, Pham PM, Pham PT. Vasopressin excess and hyponatremia. Am J Kidney Dis. 2006 May. 47 (5):727-37. [QxMD MEDLINE Link]. [Full Text].

  26. Smith D, Moore K, Tormey W, Baylis PH, Thompson CJ. Downward resetting of the osmotic threshold for thirst in patients with SIADH. Am J Physiol Endocrinol Metab. 2004 Nov. 287 (5):E1019-23. [QxMD MEDLINE Link].

  27. Glassock RJ, Cohen AH, Danovitch G, Parsa KP. Human immunodeficiency virus (HIV) infection and the kidney. Ann Intern Med. 1990 Jan 1. 112 (1):35-49. [QxMD MEDLINE Link].

  28. Palmer BF. Hyponatraemia in a neurosurgical patient: syndrome of inappropriate antidiuretic hormone secretion versus cerebral salt wasting. Nephrol Dial Transplant. 2000 Feb. 15 (2):262-8. [QxMD MEDLINE Link].

  29. Palmer BF. Hyponatremia in patients with central nervous system disease: SIADH versus CSW. Trends Endocrinol Metab. 2003 May-Jun. 14 (4):182-7. [QxMD MEDLINE Link].

  30. Furey AT. Hyponatremia after choledochostomy and T tube drainage. Am J Surg. 1966 Dec. 112 (6):850-5. [QxMD MEDLINE Link].

  31. Skippen P, Adderley R, Bennett M, Cogswell A, Froese N, Seear M, et al. Iatrogenic hyponatremia in hospitalized children: Can it be avoided?. Paediatr Child Health. 2008 Jul. 13 (6):502-6. [QxMD MEDLINE Link].

  32. Thaler SM, Teitelbaum I, Berl T. "Beer potomania" in non-beer drinkers: effect of low dietary solute intake. Am J Kidney Dis. 1998 Jun. 31 (6):1028-31. [QxMD MEDLINE Link].

  33. Goldman MB, Luchins DJ, Robertson GL. Mechanisms of altered water metabolism in psychotic patients with polydipsia and hyponatremia. N Engl J Med. 1988 Feb 18. 318 (7):397-403. [QxMD MEDLINE Link].

  34. Danz M, Pöttgen K, Tönjes PM, Hinkelbein J, Braunecker S. Hyponatremia among Triathletes in the Ironman European Championship. N Engl J Med. 2016 Mar 10. 374 (10):997-8. [QxMD MEDLINE Link].

  35. Kratz A, Siegel AJ, Verbalis JG, Adner MM, Shirey T, Lee-Lewandrowski E, et al. Sodium status of collapsed marathon runners. Arch Pathol Lab Med. 2005 Feb. 129 (2):227-30. [QxMD MEDLINE Link].

  36. Almond CS, Shin AY, Fortescue EB, Mannix RC, Wypij D, Binstadt BA, et al. Hyponatremia among runners in the Boston Marathon. N Engl J Med. 2005 Apr 14. 352 (15):1550-6. [QxMD MEDLINE Link].

  37. [Guideline] Hew-Butler T, Almond C, Ayus JC, Dugas J, Meeuwisse W, Noakes T, et al. Consensus statement of the 1st International Exercise-Associated Hyponatremia Consensus Development Conference, Cape Town, South Africa 2005. Clin J Sport Med. 2005 Jul. 15 (4):208-13. [QxMD MEDLINE Link].

  38. Baker J, Cotter JD, Gerrard DF, Bell ML, Walker RJ. Effects of indomethacin and celecoxib on renal function in athletes. Med Sci Sports Exerc. 2005 May. 37 (5):712-7. [QxMD MEDLINE Link].

  39. Budisavljevic MN, Stewart L, Sahn SA, Ploth DW. Hyponatremia associated with 3,4-methylenedioxymethylamphetamine ("Ecstasy") abuse. Am J Med Sci. 2003 Aug. 326 (2):89-93. [QxMD MEDLINE Link].

  40. Feldman BJ, Rosenthal SM, Vargas GA, Fenwick RG, Huang EA, Matsuda-Abedini M, et al. Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med. 2005 May 5. 352 (18):1884-90. [QxMD MEDLINE Link].

  41. Trivelli A, Ghiggeri GM, Canepa A, Oddone M, Bava G, Perfumo F. Hyponatremic-hypertensive syndrome with extensive and reversible renal defects. Pediatr Nephrol. 2005 Jan. 20 (1):102-4. [QxMD MEDLINE Link]. [Full Text].

  42. Sherlock M, O'Sullivan E, Agha A, Behan LA, Owens D, Finucane F, et al. Incidence and pathophysiology of severe hyponatraemia in neurosurgical patients. Postgrad Med J. 2009 Apr. 85 (1002):171-5. [QxMD MEDLINE Link]. [Full Text].

  43. Zenenberg RD, Carluccio AL, Merlin MA. Hyponatremia: evaluation and management. Hosp Pract (1995). 2010 Feb. 38 (1):89-96. [QxMD MEDLINE Link].

  44. Zeidel ML. Hyponatremia: mechanisms and newer treatments. Endocr Pract. 2010 Sep-Oct. 16 (5):882-7. [QxMD MEDLINE Link]. [Full Text].

  45. Silver SM, Kozlowski SA, Baer JE, Rogers SJ, Sterns RH. Glycine-induced hyponatremia in the rat: a model of post-prostatectomy syndrome. Kidney Int. 1995 Jan. 47 (1):262-8. [QxMD MEDLINE Link].

  46. Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Nephrol Dial Transplant. 2014 Apr. 29 Suppl 2:i1-i39. [QxMD MEDLINE Link].

  47. George JC, Zafar W, Bucaloiu ID, Chang AR. Risk Factors and Outcomes of Rapid Correction of Severe Hyponatremia. Clin J Am Soc Nephrol. 2018 Jul 6. 13 (7):984-992. [QxMD MEDLINE Link].

  48. Adrogué HJ, Madias NE. Hyponatremia. N Engl J Med. 2000 May 25. 342 (21):1581-9. [QxMD MEDLINE Link]. [Full Text].

  49. Vachharajani TJ, Zaman F, Abreo KD. Hyponatremia in critically ill patients. J Intensive Care Med. 2003 Jan-Feb. 18 (1):3-8. [QxMD MEDLINE Link]. [Full Text].

  50. Perianayagam A, Sterns RH, Silver SM, Grieff M, Mayo R, Hix J, et al. DDAVP is effective in preventing and reversing inadvertent overcorrection of hyponatremia. Clin J Am Soc Nephrol. 2008 Mar. 3 (2):331-6. [QxMD MEDLINE Link].

  51. Krisanapan P, Vongsanim S, Pin-On P, Ruengorn C, Noppakun K. Efficacy of Furosemide, Oral Sodium Chloride, and Fluid Restriction for Treatment of Syndrome of Inappropriate Antidiuresis (SIAD): An Open-label Randomized Controlled Study (The EFFUSE-FLUID Trial). Am J Kidney Dis. 2020 Aug. 76 (2):203-212. [QxMD MEDLINE Link].

  52. Jovanovich AJ, Berl T. Where vaptans do and do not fit in the treatment of hyponatremia. Kidney Int. 2013 Apr. 83 (4):563-7. [QxMD MEDLINE Link].

  53. Dixon MB, Lien YH. Tolvaptan and its potential in the treatment of hyponatremia. Ther Clin Risk Manag. 2008 Dec. 4 (6):1149-55. [QxMD MEDLINE Link].

  54. Farmakis D, Filippatos G, Kremastinos DT, Gheorghiade M. Vasopressin and vasopressin antagonists in heart failure and hyponatremia. Curr Heart Fail Rep. 2008 Jun. 5 (2):91-6. [QxMD MEDLINE Link].

  55. FDA limits use of tolvaptan due to liver injury risk. Reactions Weekly 2013;1452(1):3-3. 2013.

  56. Rondon-Berrios H, Tandukar S, Mor MK, Ray EC, Bender FH, Kleyman TR, et al. Urea for the Treatment of Hyponatremia. Clin J Am Soc Nephrol. 2018 Nov 7. 13 (11):1627-1632. [QxMD MEDLINE Link].

  57. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006 Nov 16. 355 (20):2099-112. [QxMD MEDLINE Link].

  58. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007 Mar 28. 297 (12):1319-31. [QxMD MEDLINE Link].

  59. Santos BC, Chevaile A, Hébert MJ, Zagajeski J, Gullans SR. A combination of NaCl and urea enhances survival of IMCD cells to hyperosmolality. Am J Physiol. 1998 Jun. 274 (6):F1167-73. [QxMD MEDLINE Link].

  60. Ayus JC, Wheeler JM, Arieff AI. Postoperative hyponatremic encephalopathy in menstruant women. Ann Intern Med. 1992 Dec 1. 117 (11):891-7. [QxMD MEDLINE Link].

  61. Ruzek KA, Campeau NG, Miller GM. Early diagnosis of central pontine myelinolysis with diffusion-weighted imaging. AJNR Am J Neuroradiol. 2004 Feb. 25 (2):210-3. [QxMD MEDLINE Link].

  62. Yu J, Zheng SS, Liang TB, Shen Y, Wang WL, Ke QH. Possible causes of central pontine myelinolysis after liver transplantation. World J Gastroenterol. 2004 Sep 1. 10 (17):2540-3. [QxMD MEDLINE Link].

  63. Doshi SM, Shah P, Lei X, Lahoti A, Salahudeen AK. Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes. Am J Kidney Dis. 2012 Feb. 59 (2):222-8. [QxMD MEDLINE Link].

  64. Rhee CM, Ayus JC, Kalantar-Zadeh K. Hyponatremia in the Dialysis Population. Kidney Int Rep. 2019 Jun. 4 (6):769-780. [QxMD MEDLINE Link].

  65. Corona G, Giuliani C, Verbalis JG, Forti G, Maggi M, Peri A. Hyponatremia improvement is associated with a reduced risk of mortality: evidence from a meta-analysis. PLoS One. 2015. 10 (4):e0124105. [QxMD MEDLINE Link].

Author

Seyed Mehrdad Hamrahian, MD Associate Professor of Medicine (Nephrology), Sidney Kimmel Medical College of Thomas Jefferson University; Director of American Society of Hypertension-Designated Jefferson Hypertension Center; Medical Director, Jefferson Nephrology Outpatient Clinic; Medical Director, Jefferson Home Hemodialysis Program; Medical Director of Chronic Dialysis Unit, DaVita City Line Dialysis

Seyed Mehrdad Hamrahian, MD is a member of the following medical societies: American Heart Association, American Society of Nephrology

Disclosure: Nothing to disclose.

Coauthor(s)

Omar H Maarouf, MD Assistant Professor of Medicine, Sidney Kimmel Medical College of Thomas Jefferson University; Director of Acute Dialysis Unit, Associate Program Director of Renal Fellowship, Renal Consultant, Division of Nephrology, Department of Medicine, Magee Rehabilitation Hospital

Omar H Maarouf, MD is a member of the following medical societies: American Society of Nephrology, National Kidney Foundation

Disclosure: Nothing to disclose.

Eric E Simon, MD Professor of Medicine, Chief, Section of Nephrology and Hypertension, Tulane University School of Medicine; Director, Nephrology Training, Medical Director, Dialysis Clinic, Inc, Canal Street

Eric E Simon, MD is a member of the following medical societies: American Federation for Medical Research, American Heart Association, American Physiological Society, American Society for Cell Biology, American Society of Nephrology, Central Society for Clinical and Translational Research, International Society of Nephrology, National Kidney Foundation, Phi Beta Kappa, Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Eleanor Lederer, MD, FASN Professor of Medicine, Chief, Nephrology Division, Director, Nephrology Training Program, Director, Metabolic Stone Clinic, Kidney Disease Program, University of Louisville School of Medicine; Consulting Staff, Louisville Veterans Affairs Hospital

Eleanor Lederer, MD, FASN is a member of the following medical societies: American Association for the Advancement of Science, American Society for Bone and Mineral Research, American Society of Nephrology, American Society of Transplantation, International Society of Nephrology, Kentucky Medical Association, National Kidney Foundation

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: American Society of Nephrology<br/>Received income in an amount equal to or greater than $250 from: Healthcare Quality Strategies, Inc.

Chief Editor

Vecihi Batuman, MD, FASN Huberwald Professor of Medicine, Section of Nephrology-Hypertension, Interim Chair, Deming Department of Medicine, Tulane University School of Medicine

Vecihi Batuman, MD, FASN is a member of the following medical societies: American College of Physicians, American Society of Hypertension, American Society of Nephrology, International Society of Nephrology, Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

Which hyponatremia osmolality classification is associated with high osmolality?

Hypertonic Hyponatremia. In patients with hypertonic hyponatremia, the hyponatremia is associated with increased serum osmolality (<95 mOsm/L). This condition occurs because of the presence of an osmotically active substance in the plasma, such as glucose, which results in hypertonicity.

Which of the following electrolytes are lost as a result of vomiting *?

The vomiting of gastric or intestinal contents most commonly involves the loss of fluid that contains chloride, potassium, sodium, and bicarbonate. The sequelae of these losses include dehydration along with hyponatremia, hypochloremia, and hypokalemia.

Which condition exhibits blood values with a low pH and a low plasma bicarbonate concentration?

With metabolic acidosis, “acidosis” refers to a process that lowers blood pH below 7.35, and “metabolic” refers to the fact that it's a problem caused by a decrease in the bicarbonate HCO3− concentration in the blood.

What percentage of potassium excreted daily leaves the body by way of the kidneys?

Potassium. The kidney normally excretes between 90 and 95% of our daily K+ intake.